Ceruloplasmin Test · Blood

If your standard blood panel comes back clean but you still want to know whether low-grade inflammation, iron mishandling, or liver stress is happening beneath the surface, ceruloplasmin (CP) is one of the few markers that sits at the intersection of all three. A single reading can point toward chronic inflammatory burden that predicts heart disease years before a cardiac event, flag copper metabolism problems that damage the brain and liver, or reveal iron overload patterns that standard iron panels miss entirely.

Ceruloplasmin is not part of any routine panel. You have to ask for it. That makes it a blind spot for most people, even those who test regularly. Whether your concern is cardiovascular risk, unexplained neurological symptoms, liver health, or a family history of Wilson disease, this protein gives you information that no other single test provides.

What Ceruloplasmin Does in Your Body

Ceruloplasmin is a large protein made almost entirely by your liver. It carries about 95% of the copper circulating in your blood and contains six to seven copper atoms woven into its structure. Its most important job is acting as a ferroxidase, an enzyme that converts iron from a reactive, potentially dangerous form (called ferrous iron) into a safer form (called ferric iron) that can be loaded onto transferrin, the main iron transport protein in blood.

This iron conversion step matters because uncontrolled reactive iron generates free radicals, unstable molecules that damage cell membranes and DNA. By keeping iron in check, ceruloplasmin acts as one of your body's built-in antioxidant defenses. At the same time, ceruloplasmin is what doctors call an acute phase protein: your liver produces more of it whenever there is inflammation, infection, or tissue injury. That dual role, part copper transporter, part inflammation signal, is what makes it so useful as a biomarker.

Heart Disease Risk

Elevated ceruloplasmin is one of the more consistent inflammatory predictors of coronary heart disease. A systematic review covering 18 observational studies found that higher ceruloplasmin levels were directly linked to increased risk of coronary heart disease across most of the included studies.

The strongest prospective data come from a study of 4,177 adults undergoing elective coronary angiography with three-year follow-up. People in the highest ceruloplasmin quartile had about 2.4 times the risk of heart attack compared to those in the lowest quartile (hazard ratio 2.35, 95% confidence interval 1.79 to 3.09). After adjusting for age, sex, diabetes, blood pressure, LDL cholesterol (low-density lipoprotein cholesterol, the primary cholesterol particle linked to artery disease), HDL cholesterol (high-density lipoprotein cholesterol, the protective form), triglycerides, hs-CRP (high-sensitivity C-reactive protein, another inflammation marker), and kidney function, ceruloplasmin still independently predicted major adverse cardiovascular events: about 55% higher risk comparing high to low levels.

Adding ceruloplasmin to a standard risk model improved the ability to correctly reclassify patients by nearly 10% (net reclassification improvement 9.6%). In other words, ceruloplasmin told cardiologists something that traditional risk factors, including CRP, did not.

What this means for you: if you already know your cholesterol and CRP numbers look fine but have a family history of heart disease or other reasons for concern, ceruloplasmin adds an independent layer of risk information. An elevated result alongside even modest CRP elevation paints a different picture than either marker alone.

Heart Failure

In people with existing heart failure, ceruloplasmin tracks disease severity with surprising precision. A study of 552 heart failure patients found that those with peak oxygen consumption at or below 16 mL/kg/min (a measure of how well the heart supports exercise) had significantly higher ceruloplasmin than those with better exercise capacity. Ceruloplasmin also correlated with worse functional class, higher levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide, the standard heart failure blood marker), and greater oxidative damage to cells.

A separate study of 741 heart failure patients referred as potential heart transplant candidates tracked outcomes over one year. Patients in the top quartile of ceruloplasmin (35.9 mg/dL and above) had roughly twice the risk of death or transplant compared to those in the lower three quartiles. When ceruloplasmin and NT-proBNP were both in their highest quartiles, the combined risk was about four times higher than when both were low. Even after adjusting for other clinical variables, the combination of high ceruloplasmin and high NT-proBNP remained an independent predictor of one-year death or transplant.

If you are managing heart failure, adding ceruloplasmin to your NT-proBNP tracking gives your care team a more complete view of both the inflammatory and blood-flow burden your heart is carrying.

Kidney Disease in Diabetes

For men with type 2 diabetes, higher baseline ceruloplasmin independently predicted progression of diabetic nephropathy (kidney damage caused by diabetes) in a study of 643 Korean men. Those in the highest third of ceruloplasmin had roughly three times the risk of worsening kidney damage compared to those in the lowest third, even after controlling for other risk factors.

If you have type 2 diabetes and your standard kidney markers like creatinine and eGFR (estimated glomerular filtration rate, a measure of how well your kidneys filter waste) still look normal, an elevated ceruloplasmin could be an early signal that kidney damage is beginning. This is the kind of test that catches a trajectory before standard markers cross a threshold.

Parkinson's Disease and Brain Iron

On the other end of the spectrum, low ceruloplasmin tells a very different story. In Parkinson's disease, lower serum ceruloplasmin has been linked to younger age of onset. A study of 131 patients found that those who developed Parkinson's at a younger age had significantly lower ceruloplasmin levels than those with later-onset disease.

A brain imaging study of 184 Parkinson's patients showed that lower ceruloplasmin was associated with more widespread iron accumulation in brain structures that help control movement, including the substantia nigra, putamen, and red nucleus. Without adequate ceruloplasmin to convert reactive iron into a safe form, iron builds up in brain tissue and drives oxidative damage to neurons (the cells that carry electrical signals in the brain).

Alterations in ceruloplasmin and what researchers call non-ceruloplasmin copper (the fraction of blood copper not bound to ceruloplasmin) have also been used to identify a subtype of Alzheimer's disease. These copper-related patterns may help distinguish different disease mechanisms within the broader Alzheimer's category.

Wilson Disease and Genetic Conditions

The most established clinical use of ceruloplasmin is in diagnosing Wilson disease, a genetic disorder caused by mutations in the ATP7B gene, which tells the liver how to process and excrete copper. When this gene is defective, the liver cannot properly incorporate copper into ceruloplasmin or remove excess copper through bile. The result is copper accumulation in the liver, brain, and other organs.

Traditionally, a ceruloplasmin below 20 mg/dL has been a key diagnostic criterion. A large study of 4,048 patients (297 with confirmed Wilson disease) found that the average ceruloplasmin in Wilson disease patients was about 5 mg/dL, compared to roughly 29 mg/dL in those without the disease. At the traditional 20 mg/dL cutoff, sensitivity was 99% and specificity was about 81%. A stricter cutoff of 15 mg/dL raised specificity to 95.5% while keeping sensitivity at 95.6%.

A rarer but related condition, aceruloplasminemia, involves mutations in the ceruloplasmin gene itself. Without functional ceruloplasmin, iron accumulates in the liver, pancreas, brain, and eyes, causing a characteristic pattern: mild anemia that doesn't respond to iron supplements, very high ferritin (the body's iron storage protein), low transferrin saturation, diabetes, retinal degeneration, and progressive neurological decline. Early diagnosis, often triggered by the unusual combination of anemia plus very high ferritin, is essential for preventing irreversible brain damage.

Ceruloplasmin gene variants have also been linked to worse outcomes in NAFLD (non-alcoholic fatty liver disease). In a study of 328 patients with biopsy-confirmed NAFLD, rare ceruloplasmin gene variants were associated with about six times higher odds of elevated ferritin, increased liver iron, and more severe liver scarring.

Making Sense of Both Directions

Ceruloplasmin is not a simple "higher is worse" or "lower is better" marker. It is a two-directional marker. Very low levels point toward genetic copper-handling defects (Wilson disease, aceruloplasminemia) or severe liver failure, conditions where the body cannot make enough of this protective protein. High levels point toward chronic inflammation, oxidative damage, and increased cardiovascular or metabolic risk. The sweet spot is somewhere in the middle, where your liver is producing enough ceruloplasmin to manage iron and copper safely, without being driven to overproduce it by inflammatory signals.

This means the clinical question changes depending on which direction your result falls. A low reading triggers a workup for copper metabolism disorders and liver synthetic function. A high reading triggers investigation into inflammatory burden, cardiovascular risk, and metabolic stress. Both extremes carry risk, just through very different mechanisms.

Reference Ranges

Most clinical labs report ceruloplasmin using protein-measuring techniques (called immunologic assays) in mg/dL. The ranges below are drawn from published research, including a large study of over 3,700 non-Wilson disease patients. Women typically run higher than men, and levels vary with age, rising in early childhood, declining through adolescence, and rising again after age 60. Your lab may report slightly different numbers depending on assay and population.

Compare your results within the same lab over time for the most meaningful trend. A single reading outside the normal range is a prompt to investigate, not a diagnosis.

When Results Can Be Misleading

Ceruloplasmin is an acute phase protein, which means anything that triggers an inflammatory response can push your level up temporarily and make a single reading unrepresentative of your baseline. This is the single biggest source of false highs.

• Acute illness or recent surgery: Any significant infection, injury, or surgical procedure can elevate ceruloplasmin for days to weeks. If you had a cold, flu, or any illness in the week before your blood draw, your result may be artificially high. Wait at least two to three weeks after recovery before testing.
• Estrogen exposure: Oral contraceptives containing synthetic estrogen can roughly double ceruloplasmin levels, and pregnancy can triple them. This is a real increase in liver production driven by estrogen, not an assay artifact, but it does not indicate the inflammatory or cardiovascular risk that naturally elevated ceruloplasmin signals. Levels return to normal within about four weeks of stopping oral contraceptives and about six weeks after delivery. If you are on hormonal contraceptives, your ceruloplasmin will be high and this is expected, not a sign of disease.
• Age and sex: Women naturally run higher than men at any age, and levels rise again after age 60 in both sexes. A ceruloplasmin of 33 mg/dL in a 70-year-old woman is very different from 33 mg/dL in a 30-year-old man.
• Severe liver disease: Paradoxically, advanced liver failure can lower ceruloplasmin because the liver can no longer synthesize it adequately, even during inflammation. A low result in someone with known liver disease does not necessarily mean Wilson disease. It may reflect synthetic failure.

Tracking Your Trend

A single ceruloplasmin reading gives you a snapshot. A series of readings over time gives you a trajectory, and the trajectory is far more useful. The European Biological Variation Study (EuBIVAS), which measured week-to-week variability in 91 healthy adults sampled over 10 consecutive weeks, found that ceruloplasmin has modest within-person biological variation, meaning that real changes in your level are distinguishable from normal fluctuation if you test under consistent conditions.

The study generated reference change values, which are the minimum percentage change between two results that qualifies as a real shift rather than random noise. Using these values is the most reliable way to decide whether a change in your ceruloplasmin is meaningful. In practical terms: get a baseline when you are healthy and not on estrogen-containing medications, retest in three to six months if you are making lifestyle or treatment changes, and then at least annually if you are tracking cardiovascular or inflammatory risk.

If your ceruloplasmin is consistently trending upward over multiple readings, that pattern suggests increasing inflammatory burden or metabolic stress worth investigating, even if each individual reading falls within the normal range. Conversely, a declining trend in someone with neurological symptoms or iron overload could signal worsening copper metabolism problems.

What To Do With an Abnormal Result

Your next steps depend entirely on which direction the result is abnormal.

If ceruloplasmin is low (below 20 mg/dL): order serum copper, 24-hour urinary copper, and a complete liver panel. If copper is also low and you are under 55 with unexplained liver disease or neurological symptoms, Wilson disease needs to be evaluated, ideally with a hepatologist or geneticist who can arrange ATP7B gene testing. If ferritin is very high but transferrin saturation is paradoxically low, aceruloplasminemia should be considered. A specialized microscope eye exam (called a slit lamp exam) looking for Kayser-Fleischer rings (copper deposits in the cornea) is part of the standard Wilson disease workup.

If ceruloplasmin is high (above 35 mg/dL): first rule out estrogen exposure (pregnancy, oral contraceptives, hormone replacement therapy) and recent acute illness. If neither explains the elevation, check hs-CRP and ferritin to assess inflammatory and iron status. In someone with known cardiovascular risk factors, an elevated ceruloplasmin adds independent prognostic information and may strengthen the case for aggressive lipid and blood pressure management. In someone with type 2 diabetes, pair it with kidney function markers like cystatin C and urine albumin-to-creatinine ratio to catch early nephropathy. For persistently elevated results without an obvious cause, consider consulting a cardiologist or internist who can integrate it with your broader risk profile.